Exercise should be first line of defence against elevated blood pressure
Healthcare experts have recommended exercise as a first-line treatment for mild to moderate-risk blood pressure and cholesterol.
Cardiovascular
PharmaEssentia resubmits BLA for polycythemia vera therapeutic
PharmaEssentia USA resubmits BLA to the FDA, seeking approval for ropeginterferon alfa-2b-njft for polycythemia vera...
Israel assesses myocarditis cases linked to Pfizer-BioNTech Covid-19 vaccine
The Israel Health Ministry is examining a small number of cases related to inflammation of...
A segment of Covid-19 survivors face possible long-term complications
There is growing evidence that about 10% of people with Covid-19 will go on to...
Heart Disease Deaths on the Rise in Young Women
As February is American Heart Month in the US, GlobalData epidemiologists are highlighting findings from...
Humacyte agrees SPAC merger to go public with bioengineered tissue tech
Human tissue bioengineering biotech Humacyte has entered into a business combination agreement with special purpose acquisition company (SPAC) Alpha Healthcare Acquisition Corp (AHAC).
US judge orders BMS, Sanofi to pay $834m for illegal marketing of Plavix
US Judge Dean Ochiai has ordered Bristol-Myers Squibb (BMS) and Sanofi to pay over $834m to the state of Hawaii for illegally marketing their blood-thinning drug Plavix.
China approves AstraZeneca’s Forxiga for heart failure
China’s National Medical Products Administration (NMPA) has approved AstraZeneca’s Forxiga (dapagliflozin) for heart failure with reduced ejection fraction (HFrEF) in adults with and without type-2 diabetes.
AstraZeneca divests Atacand commercial rights to Cheplapharm
AstraZeneca has completed the divestment of commercial rights to Atacand (candesartan cilexetil) and Atacand Plus in over 70 countries to German pharmaceutical firm Cheplapharm Arzneimittel.
Takeda to divest non-core assets to Hasten Biopharmaceutic for $322m
Takeda Pharmaceutical Company has signed an agreement to divest a portfolio of five non-core prescription pharmaceutical assets sold in China to Hasten Biopharmaceutic for $322m.
AstraZeneca’s heart failure treatment Forxiga gets approval in Japan
The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved AstraZeneca’s Forxiga (dapagliflozin) for treating patients with chronic heart failure (HF) who are receiving standard of care in the country.
